Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Microbiology Department, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Clin Nutr. 2020 Aug;39(8):2358-2367. doi: 10.1016/j.clnu.2019.11.008. Epub 2019 Nov 9.
BACKGROUND & AIMS: To assess the effects of pro-/synbiotic treatment on patients with colorectal cancer (CRC), a systematic review was conducted on randomized controlled trials.
International databanks (ISI Web of Science, PubMed, Scopus, and Google Scholar) were searched from January 2007 to December 2017 using the following keywords: 'colorectal cancer' and 'probiotics'. The search was restricted to original articles published in English. Reference lists of all related studies were also reviewed to find other relevant publications. The statistical analysis was performed using SPSS software version 18.0 (IBM, NY, USA). Also, p < .05 was regarded as statistically significant.
A total of 21 clinical trials were retrieved, involving 1831 patients subjected to elective colorectal surgery. The studies included in this review have investigated the effects of probiotics on different aspects of colorectal cancer treatment (p < .05). According to the present study results, probiotics could significantly decrease inflammatory factors, chemotherapy side effects, severe diarrhea, postoperative infectious complications, and duration of antibiotic therapy; shift fecal microbiota in favor of Actinobacteria; and change the tumor tissue microbiota (p < .05).
Based on the present review, the preoperative use of pro-/synbiotics as prophylaxis for patients with CRC could improve clinical outcomes. More detailed data about the types of probiotic species and the optimal consumption dose of pro-/synbiotics should be taken in to account in future meta-analysis reviews.
为了评估促生/共生治疗对结直肠癌(CRC)患者的影响,我们对随机对照试验进行了系统评价。
国际数据库(ISI Web of Science、PubMed、Scopus 和 Google Scholar)于 2007 年 1 月至 2017 年 12 月进行了检索,使用了以下关键词:“结直肠癌”和“益生菌”。检索仅限于发表在英文期刊上的原始文章。还查阅了所有相关研究的参考文献列表,以找到其他相关出版物。使用 SPSS 软件版本 18.0(IBM,NY,USA)进行统计分析。另外,p<.05 被认为具有统计学意义。
共检索到 21 项临床试验,涉及 1831 例接受择期结直肠手术的患者。本综述纳入的研究调查了益生菌对结直肠癌治疗不同方面的影响(p<.05)。根据本研究结果,益生菌可显著降低炎症因子、化疗副作用、严重腹泻、术后感染性并发症和抗生素治疗时间;有利于粪菌向放线菌转移;并改变肿瘤组织微生物群(p<.05)。
基于本综述,术前使用促生/共生治疗作为 CRC 患者的预防措施,可以改善临床结局。在未来的荟萃分析综述中,应更详细地考虑益生菌种类和促生/共生治疗最佳使用剂量的数据。